Ronald DePinho, M.D., begins his presidency of MD Anderson today, Thursday, Sept. 1.
"To eliminate cancer around the world - what could be a more clear and noble mission? Cancer is a daunting foe and too many people still succumb to it. Your many discoveries and extraordinary advances in care have moved the entire field forward over the past 70 years, " DePinho said Thursday in a message to MD Anderson employees. "While much work remains in the lab, the clinic, the classroom, the community and the world, MD Anderson has the people, commitment and resources to conquer this dreaded disease. We will make that happen.
I intend to focus on where the greatest new opportunities lie for us, especially in basic science, in science-driven clinical care, and in education. And I will help you build upon the expertise, compassion and quality of our immense and unmatched clinical operation. I also will not shrink from the task of preparing MD Anderson for continued achievement in a challenging economic climate and era of health care reform."
DePinho is internationally recognized for basic and translational research in cancer, aging and age-associated degenerative disorders. He's the fourth full-time president of MD Anderson.
Learn more about DePinho's background and research.
DePinho succeeds John Mendelsohn, M.D., who remains on MD Anderson faculty, returning to clinical and translational research as co-director of a new Institute for Personalized Cancer Therapy.